COMMUNIQUÉS West-GlobeNewswire
-
Intuitive Collaborates with Deion “Coach Prime” Sanders to Raise Patient Awareness of Surgical Options
27/07/2026 -
Rose Hill Life Sciences Appoints Jama Pitman as Chief Executive Officer
27/07/2026 -
CurePSP Invests in the Next Generation of PSP and CBD Researchers with Student Fellowship Awards
27/07/2026 -
Landmark 10-Year Study Strengthens Long-Term Evidence Supporting Focal Therapy
27/07/2026 -
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
27/07/2026 -
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
27/07/2026 -
Micron Biomedical Secures $4.5 Million Federal Contract to Develop First Dissolvable Microarray Radiation/Nuclear Medical Countermeasure
27/07/2026 -
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
27/07/2026 -
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
27/07/2026 -
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
27/07/2026 -
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
27/07/2026 -
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
27/07/2026 -
Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
27/07/2026 -
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
27/07/2026 -
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
27/07/2026 -
Picard Medical Receives NYSE American Acceptance of Compliance Plan
27/07/2026 -
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
27/07/2026 -
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
27/07/2026 -
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
27/07/2026
Pages